Retatrutide
Triple agonist (GLP-1 / GIP / glucagon) studied for body composition and metabolic regulation research.
Testing & quality
Every batch is supplier-tested for identity and purity and randomly verified by independent third-party HPLC and mass spectrometry.
Compound classification
Synthetic 39-amino-acid triple receptor agonist peptide.
Mechanism studied in the literature
Engineered to bind and activate three incretin/metabolic receptors simultaneously: GLP-1, GIP, and glucagon. In preclinical models this combined agonism is studied for its effects on insulin signaling, lipolysis, and energy expenditure.
Research areas
- Body composition and adipose tissue research
- Glycemic regulation and incretin biology
- Hepatic lipid metabolism (preclinical NAFLD/NASH models)
- Comparative agonist studies vs. tirzepatide and semaglutide
Storage
Lyophilized powder: store at -20°C protected from light for long-term stability (up to 24 months). After reconstitution: refrigerate at 2-8°C and use within 28 days under sterile laboratory conditions.
Reconstitution (laboratory)
Reconstitute lyophilized powder with bacteriostatic water or sterile water for injection (USP grade). Swirl gently — do not shake — until fully dissolved.
Notes
Sold strictly as a reference research compound for in-vitro laboratory study. Independently HPLC/MS verified at 99%+ purity.
Related research peptides
Tirzepatide
Dual GIP / GLP-1 receptor agonist studied for glycemic control and metabolic pathway research.
MOTS-c
Mitochondrial-derived peptide studied for insulin sensitivity, energy expenditure, and metabolic homeostasis.
SLU-PP-322
ERR agonist researched for exercise mimetic effects and mitochondrial biogenesis.
AOD-9604
HGH fragment 176-191 studied for lipolytic and metabolic pathway research.